Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701503 | 0.87 | KMT2A (0.55) | KMT2AKDM4EALDH1A1POLBNPC1 | |
| SCHEMBL4703040 | 0.85 | KDM4E (0.51) | KMT2AKDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1318007 | 0.84 | MAOB (0.54) | KMT2AKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL16466479 | 0.82 | KDM4E (0.56) | KMT2AKDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15832745 | 0.82 | KDM4E (0.56) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL30009450 | 0.80 | KDM4E (0.80) | KMT2AKDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL22345013 | 0.80 | KDM4E (0.80) | KMT2AKDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL129159 | 0.79 | HDAC1 (0.57) | KMT2AKDM4EALDH1A1HPGDAKR1C3 | |
| SCHEMBL2007115 | 0.78 | ALDH1A1 (0.47) | KMT2AKDM4ECYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL881297 | 0.78 | LMNA (0.59) | KMT2ACYP1A2CYP2C9CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46558-E1 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-RE46558-E1 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9381187-B2 | Radiation countermeasure agents | PALOMA PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381187-B2 | Radiation countermeasure agents | PALOMA PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2015154047-A1 | NOVEL METHODS | RESTORGENEX CORPORATION (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20140221471-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221471-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140105920-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS INC (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140105920-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS INC (US) | 2014-04-17 | — | — | US | disclosed |
| US-8475776-B2 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8475776-B2 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110268679-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. | 2011-11-03 | — | — | US | disclosed |
| US-20110268679-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. | 2011-11-03 | — | — | US | disclosed |
| US-20110021618-A1 | METHODS OF TREATING FIBROTIC DISORDERS | PALOMA PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021618-A1 | METHODS OF TREATING FIBROTIC DISORDERS | PALOMA PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20070197567-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197567-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268679-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, TYR | KMT2A 2995/4885KDM4E 1817/4885CYP1A2 606/4885 |
| US-20140221471-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, TYR | KMT2A 2995/4885KDM4E 1817/4885CYP1A2 606/4885 |
| US-20140105920-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, FLT1 | KMT2A 4155/4885KDM4E 3557/4885CYP1A2 3476/4885 |
| US-20110021618-A1 | METHODS OF TREATING FIBROTIC DISORDERS | COL2A1, MMP1, COL1A1 | KMT2A 4235/4885KDM4E 2823/4885CYP1A2 3402/4885 |
| US-20070197567-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, HDGF | KMT2A 4194/4885KDM4E 3839/4885CYP1A2 2765/4885 |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | MKI67, VEGFA, TYR | KMT2A 2995/4885KDM4E 1817/4885CYP1A2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.